Who founded Novan, Inc.?

Novan, Inc. was founded by Mark Schoenfisch, Nathan Stasko.

Who are Novan, Inc.'s investors?

Novan, Inc.'s investors include Hatteras Venture Partners.

How much funding has Novan, Inc. raised?

Novan, Inc. has disclosed $86.3M raised across 3 of its 5 known rounds.

Where is Novan, Inc. headquartered?

Novan, Inc. is headquartered in Durham, US.

Novan, Inc.

Durham, US · 2 known investors

Find your way into Novan, Inc.

Paths you didn't know you had: your email and LinkedIn already hold routes to the Novan, Inc. team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Pelthos Therapeutics is a biopharmaceutical company that develops and commercializes topical treatments for infectious skin conditions and parasitic infestations. The company markets approved and pipeline therapeutic products targeting patient populations with limited treatment options.

Biotech Healthtech Medical Devices

Founders & leadership

Mark SchoenfischCo-founder

Nathan StaskoCo-founder

Board

Robert A IngramBoard director

Sean MurphyBoard director

W Kent GeerBoard director

John W PalmourBoard director

F Neal HunterBoard director

G Kelly MartinBoard director

Investors · 2

Hatteras Venture PartnersinferredResearch Triangle · $500K – $4M

How we know: board seat on SEC Form D · Not right? Tell us

Also in the syndicate · 1

Reedy Creek Investments LLC

Reported raises · per SEC filings

Form D private placements

$86.3M disclosed across 3 of 5 rounds · 2014–2020

▶$32.8MraisedDec 2015 · 172 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Mark SchoenfischDirector
G. Kelly MartinDirector
Sean MurphyDirector
F Neal HunterDirector
W. Kent GeerDirector
John W PalmourDirector
Richard PetersonExecutive Officer
Robert A IngramDirector
Nathan StaskoExecutive Officer, Director

Offering amount: $32.8M
Amount sold: $32.8M
First sale: Dec 2015
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$50MraisedMar 2015 · 91 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Sean MurphyDirector
W Kent GeerDirector
John W PalmourDirector
Mark SchoenfischExecutive Officer, Director
Nathan StaskoExecutive Officer, Director
F Neal HunterDirector
Robert A IngramDirector
G Kelly MartinDirector

Offering amount: $50M
Amount sold: $50M
First sale: Aug 2014
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$3.5MraisedMar 2014 · 36 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

F Neal HunterDirector
Mark SchoenfischExecutive Officer, Director
Nathan StaskoExecutive Officer, Director
Robert A IngramDirector
John W PalmourDirector

Offering amount: $3.5M
Amount sold: $3.5M
First sale: Feb 2014
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Non-dilutive funding · 12 SBIR/STTR awards

Federal grants — no equity taken

Agency	Phase	Year	Amount
National Institutes of Health (NIH)National Institutes of Health	Phase II	2020	$1.1M
National Institutes of Health (NIH)National Institutes of Health	Phase I	2019	$223.1K
U.S. ArmyArmy	Phase II	2012	$779.6K
National Science Foundation	Phase II	2012	$500K
National Institutes of Health (NIH)National Institutes of Health	Phase I	2012	$148.1K
National Institutes of Health (NIH)National Institutes of Health	Phase I	2011	$995.9K
National Institutes of Health (NIH)National Institutes of Health	Phase I	2011	$599K
U.S. ArmyArmy	Phase I	2011	$69.8K
National Institutes of Health (NIH)National Institutes of Health	Phase II	2010	$2.7M
National Institutes of Health (NIH)National Institutes of Health	Phase I	2010	$282K
National Science Foundation	Phase I	2010	$140.8K
National Institutes of Health (NIH)National Institutes of Health	Phase I	2008	$399.6K

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

In the news

Novan Announces $8.0 Million Registered Direct Offering Priced At-the-Market - BioSpacebiospace.com · Mar 2020

Novan Secures Up to $35 Million in Non-Dilutive Fundingglobenewswire.com · Apr 2019

Frequently asked questions

What does Novan, Inc. do?: Pelthos Therapeutics is a biopharmaceutical company that develops and commercializes topical treatments for infectious skin conditions and parasitic infestations. The company markets approved and pipeline therapeutic products targeting patient populations with limited treatment options.
Who founded Novan, Inc.?: Novan, Inc. was founded by Mark Schoenfisch, Nathan Stasko.
Who are Novan, Inc.'s investors?: Novan, Inc.'s investors include Hatteras Venture Partners.
How much funding has Novan, Inc. raised?: Novan, Inc. has disclosed $86.3M raised across 3 of its 5 known rounds.
Where is Novan, Inc. headquartered?: Novan, Inc. is headquartered in Durham, US.